<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359476</url>
  </required_header>
  <id_info>
    <org_study_id>CA183-023</org_study_id>
    <nct_id>NCT00359476</nct_id>
  </id_info>
  <brief_title>A Study of Vinflunine in Patients With Gastric Cancer</brief_title>
  <official_title>A Multicenter, Single-Arm, Phase II Study of Single-Agent Vinflunine in the Second-line Treatment of Patients With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn if vinflunine can shrink or slow the growth of cancer
      in patients with advanced or metastatic stomach cancer who have progressed on a prior
      treatment with a fluoropyrimidine or taxane-containing chemotherapy regimen. The safety of
      this treatment will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Response Rate (RR: Complete Response [CR]+Partial Response [PR], as defined by Response Evaluation Criteria in Solid Tumors [RECIST]</measure>
    <time_frame>throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of the progression free survival and overall survival</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The estimation of the disease control rate</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time to response and the duration of response</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The evaluation of the safety profile of vinflunine</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Stomach Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinflunine</intervention_name>
    <description>solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with locally advanced or metastatic gastric adenocarcinoma, including
             adenocarcinoma of the gastroesophageal junction who have progressed on a
             fluoropyrimidine or taxane-containing regimen in any combination in one prior first
             line treatment.

          -  EGOC performance status of 0,1 or 2

          -  Men and women, 18 years of age and older

        Exclusion Criteria:

          -  Patients having received more than one previous systemic chemotherapy regimen in any
             setting.

          -  Major abdominal surgery within 2 months or any other surgery under general anesthesia
             within 4 weeks

          -  Unresolved occlusive or sub-occlusive intestinal disease or any significant chronic
             intestinal disease (e.g. ulcerative colitis)

          -  Prior radiation to &gt;=30% of the bone marrow and/or radiation within 4 weeks prior to
             enrollment

          -  Acute or chronic hepatitis

          -  Known HIV infection

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms

          -  A history of additional risk factors for Torsade de Pointes (e.g., heart failure
             hypokalemia, family history of Long QT Syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Suwon-Si</city>
        <state>Gyeonggi-Do</state>
        <zip>442-723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gyeonggi-Do</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nilai</city>
        <state>Negeri Sembilan</state>
        <zip>71800</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2006</study_first_submitted>
  <study_first_submitted_qc>August 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2006</study_first_posted>
  <disposition_first_submitted>February 27, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>February 27, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 2, 2010</disposition_first_posted>
  <last_update_submitted>February 27, 2010</last_update_submitted>
  <last_update_submitted_qc>February 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <keyword>Locally advanced/metastatic gastric adenocarcinoma</keyword>
  <keyword>adenocarcinoma-gastroesophageal junction</keyword>
  <keyword>Gastric Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

